Evogene
From Wikipedia the free encyclopedia
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Company type | Public |
---|---|
TASE: EVGN NYSE: EVGN | |
Industry | Computational Biology |
Founded | 2002 |
Founder | Dr. Hagai Karchi and Dr. Rafi Meissner |
Headquarters | Rehovot, Israel |
Key people | Sarit Firon, Chairperson of Board, Ofer Haviv, President & CEO |
Subsidiaries | Biomica, Canonic, Lavie Bio, AgPlenus, Castera |
Website | www |
Evogene is a computational biology company based in Israel. Evogene Ltd. (NASDAQ:EVGN) has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence (AI), while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF (OTCQX:BASFY), Bayer (OTCPK:BAYZF), Corteva (CTVA), ICL Group Ltd. (ICL) as well as various academic and medical institutions.
References[edit]
[edit]